MK-677 Pharmacokinetics
MK-677 half-life, absorption, routes of administration, and clearance.
Oral Absorption and a 24-Hour Half-Life
MK-677's defining pharmacokinetic feature is that it is orally bioavailable and long-acting — the property that separates it from every injectable secretagogue in this library. • Oral Tmax is approximately 30 minutes to 2 hours, with a terminal elimination half-life of approximately 24 hours, dramatically longer than Ipamorelin's ~2 hours or GHRP-6's ~1 hour. • Because of this long half-life, once-daily oral dosing maintains meaningfully elevated growth hormone and IGF-1 levels across the full 24-hour period rather than producing one discrete pulse, and IGF-1 in particular stays elevated between doses due to its own longer physiological half-life. • No injection or reconstitution is required — MK-677 is dosed as an oral capsule or solution, which is the practical basis for its popularity as a lower-friction alternative to injectable GH secretagogues.
Physicochemical and PK profile
- Molecular Formula
- C27H36N4O5S
- Molecular Weight
- 528.67 g/mol
- CAS Number
- 159752-10-0
- Half-Life
- Approximately 24 hours
- Solubility
- Oral capsule/solution — no reconstitution required
- Storage
- Store capsules/solution at room temperature, away from light and moisture.
References
- MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. · Murphy MG, Plunkett LM, Gertz BJ, He W, Wittreich J, Polvino WM, Clemmons DR · 1998
- Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. · Nass R, Pezzoli SS, Oliveri MC, Patrie J, Harman SM, Carlson OD, Egan JM, Evans WS, Veldhuis JD, Thorner MO · 2008
- Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group. · Murphy MG, Bach MA, Plotkin D, Bolognese J, Ng J, Krupa D, Cerchio K, Gertz BJ · 1999
- Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. · Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ · 2001
- Ibutamoren | C27H36N4O5S | CID 9576836 - PubChem - NIH